Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Go back to Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
AGENUS (NASDAQ: AGEN) Delayed: 6.33 -0.18 (2.76%)
Previous Close $6.51    52 Week High $7.49 
Open $6.36    52 Week Low $2.61 
Day High $6.50    P/E N/A 
Day Low $6.16    EPS $-1.10 
Volume 510,113       

(NASDAQ: INKT) Delayed: 10.71 +0.65 (6.46%)
Previous Close $10.06    52 Week High $ 
Open $10.64    52 Week Low $ 
Day High $11.68    P/E N/A 
Day Low $10.18    EPS $ 
Volume 29,409